<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 19, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02152930</url>
  </required_header>
  <id_info>
    <org_study_id>NL46719.029.13</org_study_id>
    <nct_id>NCT02152930</nct_id>
  </id_info>
  <brief_title>The Effects of Fish Oil Supplements During Supervised Exercise Therapy in Patients With Intermittent Claudication</brief_title>
  <acronym>FISHTIC</acronym>
  <official_title>The Effects of Fish Oil Supplements During Supervised Exercise Therapy in Patients With Intermittent Claudication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Center Alkmaar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Center Alkmaar</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intermittent claudication (IC) is caused by peripheral arterial disease and has a high
      morbidity and mortality. Etiologic factors are similar to those of cardiovascular disease.
      Primary treatment consists of cardiovascular risk management and improvement of functional
      capacity with supervised exercise therapy (SET). A potential additional therapy is the
      administration of fish oil supplements containing high amounts of omega-3 Poly Unsaturated
      Fatty Acids (PUFAs). In earlier clinical and experimental trials omega-3 PUFA's improved
      hemorheological parameters such as erythrocyte deformability and aggregation, and a number
      of cardiovascular risk factors. Hemorheological parameters determine the blood flow in the
      microcirculation, which is of main importance in patients with IC since the macrocirculation
      is compromised. Inflammation is considered an important etiologic factor in the pathogenesis
      of atherosclerosis and contributes to peripheral arterial disease Since omega-3 PUFAs also
      have a strong anti-inflammatory effect, they might be effective in patients with IC by
      lowering the inflammatory response. In addition, visceral fat rather than obesity in general
      has been recognised as an etiologic and prognostic factor in atherosclerosis.

      We hypothesise that the administration of omega-3 PUFA's in patients with IC has a
      synergistic effect with SET and improves walking distance after SET, by improving
      hemorheological parameters resulting in a better microcirculation. Second, we hypothesise
      that omega-3 PUFA's result in a less proinflammatory of whole blood in response to ex vivo
      stimulation with endotoxin. Third, we hypothesise that omega-3 PUFA's and SET result in a
      decrease in visceral fat mass.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximal walking distance with standardised treadmill test</measure>
    <time_frame>After 12 weeks of supervised exercise therapy</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemorheological parameters</measure>
    <time_frame>After 12 weeks of supervised exercise therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visceral fat mass</measure>
    <time_frame>After 12 weeks of supervised exercise therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ex vivo cytokine production after stimulation with lipopolysaccharide</measure>
    <time_frame>After 12 weeks of supervised exercise therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the microcirculation with side stream dark field technology</measure>
    <time_frame>After 12 weeks of supervised exercise therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Bloodpressure, heart rate, cholesterol, triglycerides, hemoglobin, leucocytes, C-reactive protein, ankle brachial index,</measure>
    <time_frame>After 12 weeks of supervised exercise therapy</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Intermittent Claudication</condition>
  <arm_group>
    <arm_group_label>Supervised Exercise Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment: Supervised Exercise Therapy during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlled group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 fatty acids</intervention_name>
    <description>1000 mg of omega-3 fatty acid ethylesters, 2 times daily, for 4 weeks, followed by 12 weeks of supervised exercise therapy in combination with 2 times daily omega-3 fatty acid supplementation.</description>
    <arm_group_label>Supervised Exercise Therapy</arm_group_label>
    <other_name>Fish oil supplements</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18

          -  Newly diagnosed intermittent claudication

          -  Ankle Brachial Index &lt; 0.8 at rest or &gt; 0.15 decrease after exercise

          -  Able to perform standardised treadmill walking test for 2 min

          -  Written informed consent

        Exclusion Criteria:

          -  Unable to fill out a questionnaire (cognitive impairment or insufficient knowledge of
             the Dutch language)

          -  Heart failure or unstable cardiac status (angina pectoris class III or IV or recent
             myocardial infarction &lt; 3 months)

          -  Any illness with rapid evolution or a life expectancy &lt; 3 months

          -  Recent cerebrovascular accident (&lt; 3 months)

          -  Current use of fish oil supplements or &gt; 2 times a week dietary fish

          -  Pregnancy

          -  Fish, soybean or peanut allergy

          -  Contra indications for the use of omega-3 fatty acids

          -  Use of oral anticoagulants (coumarin derivatives)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander P.J. Houdijk, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center Alkmaar</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander P.J. Houdijk, Dr.</last_name>
    <phone>+31 72 5484444</phone>
    <email>a.p.j.houdijk@mca.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie Bakker, Drs.</last_name>
    <phone>+31 72 5484444</phone>
    <email>nathalie.bakker@mca.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Center Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <state>Noord Holland</state>
        <zip>1800AM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nathalie Bakker, Drs.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia van Wissen, Drs.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Center Alkmaar</investigator_affiliation>
    <investigator_full_name>Alexander P.J. Houdijk</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Fish oil supplements</keyword>
  <keyword>Supervised Exercise Training</keyword>
  <keyword>Walking distance</keyword>
  <keyword>Hemorheological factors</keyword>
  <keyword>Cardiovascular risk</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
